Mankind Pharma Ltd

Mankind Pharma Ltd has announced that its Board of Directors will convene on October 26, 2026. The primary agenda item is to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. Additionally, the trading window for the company's securities will remain closed until October 28, 2026, in line with insider trading regulations.

Mankind Pharma Limited announced that S.R. Batliboi & Co. LLP, the statutory auditors of its material wholly-owned subsidiary, Bharat Serums and Vaccines Limited (BSV), have resigned. The resignation is effective September 28, 2026, and is a consequence of BSV initiating voluntary liquidation proceedings under the Insolvency and Bankruptcy Code, 2016. The auditors confirmed no other material reason for their resignation. The auditors had completed the audit for the year ended March 31, 2026, and had not commenced the audit for the year ending March 31, 2027.

Mankind Pharma Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in effect from October 01, 2026, and will remain open 48 hours after the declaration of the company's unaudited standalone and consolidated financial results for the quarter and half-year ending September 30, 2026. The decision aligns with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The specific date for the Board Meeting to declare these financial results will be communicated separately.

Mankind Pharma Ltd has received an ESG rating of 68.21 from Niche99 ESG Ratings, placing it in the 'Leader' category. This rating is based on publicly available data for FY 2025-26. Notably, the company did not engage Niche99 for this rating, indicating an independent assessment by the ESG provider. The disclosure is also available on the company's website.

Mankind Pharma Ltd announced that its wholly-owned subsidiary, Bharat Serums and Vaccines Limited (BSVL), has received approval from its members for voluntary liquidation. This decision was made during an Extraordinary General Meeting held on September 7, 2026. The liquidation is subject to the approval of BSVL's creditors as per the Insolvency and Bankruptcy Code, 2016. This follows earlier preparatory activities for the liquidation process, as communicated on August 26, 2026. The company has provided detailed disclosures as required by SEBI regulations.

Mankind Pharma Ltd has announced the final update on the sale of its entire 100% stake in its wholly owned subsidiary, Broadway Hospitality Services Private Limited, to AKRK Projects LLP and its Partners. The transaction was completed on August 31, 2026. Consequently, Broadway Hospitality Services Private Limited is no longer a subsidiary of Mankind Pharma Ltd as of the same date. Details required by SEBI regulations were previously submitted on July 11, 2026.

Mankind Pharma Limited's Board of Directors has approved the integration of its wholly-owned subsidiary, Bharat Serums and Vaccines Limited (BSVL), through a voluntary liquidation process. BSVL's business will be consolidated into Mankind Pharma on a going concern basis, with Appian Properties Private Limited, a 4% shareholder, to receive cash proportionate to its stake. This move aims to drive operational efficiencies, improve organizational execution, enhance cash management, and reduce compliance requirements. The voluntary liquidation will be managed by a liquidator appointed by BSVL, adhering to the Insolvency and Bankruptcy Code.

Mankind Pharma Limited's Board of Directors has approved the integration of its wholly-owned subsidiary, Bharat Serums and Vaccines Limited (BSVL), through a voluntary liquidation process. BSVL's business will be consolidated into Mankind Pharma on a going concern basis, subject to regulatory approvals. Appian Properties Private Limited, a 4% shareholder in BSVL, will receive cash proportionate to its stake based on an independent valuation. This move aims to drive operational efficiency, improve organizational execution, enhance cash management, reduce compliance, and rationalize expenses by consolidating operations into a single entity. The voluntary liquidation will be managed by a liquidator appointed by BSVL, adhering to the Insolvency and Bankruptcy Code, 2016.

Mankind Pharma Ltd has announced an improved ESG Rating of 64, placing it in the 'Strong' category, up from a previous rating of 57 ('Adequate'). The company's Core ESG Rating also saw an increase to 71 from 60. CRISIL ESG Ratings & Analytics independently assigned this rating based on FY2026 disclosures and publicly available information, without direct engagement from the company. This positive development highlights the company's enhanced environmental, social, and governance performance.

Mankind Pharma Limited has entered into an exclusive in-licensing and marketing agreement with China-based Chongqing Chenan Biopharmaceutical Co., Ltd. for the commercialization of Insulin Degludec and Insulin Degludec + Aspart Combination in India. This partnership aims to strengthen Mankind Pharma's presence in the diabetes segment and expand its injectable diabetes portfolio. The agreement aligns with Mankind Pharma's strategy of leveraging global innovation through strategic partnerships and in-licensing opportunities, particularly from China's growing biopharmaceutical sector. The company plans to enhance patient access to advanced diabetes therapies in India.